Anticholinergics, executive function, and cognitive/behavioral changes in Down syndrome.
Аннотация
INTRODUCTION
Anticholinergic (AC) medication use is considered a risk factor for cognitive impairment and deterioration in the general population; yet, this has not been examined in Down syndrome (DS), a disorder with high dementia rates.
METHODS
Family members of 108 young adults with DS (18-39 years) reported on their loved one's medication use, executive function, and changes in cognition and behavior using a dementia screener. Medications were coded for their AC potency using the CRIDECO Anticholinergic Load Scale (CALS).
RESULTS
Forty percent of the sample was taking at least one medication with a CALS AC potency of ≥1. These individuals were reported to have greater executive function difficulties and more changes in cognition/behavior relative to those not taking AC medications.
DISCUSSION: AC medication use may represent a modifiable risk factor for cognitive deterioration in adults with DS; more research on this topic, particularly with older adults with DS, is needed.
HIGHLIGHTS: Identifying modifiable risk factors for dementia in Down syndrome (DS) is critical. A risk factor studied in the general population is anticholinergic (AC) medication. This risk factor has not been studied in DS, a high-risk group. AC medication use was associated with everyday cognitive challenges in young adults with DS. Longitudinal studies across adulthood, including older adults with DS, are needed.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.